Ardelyx shares surged 22% in premarket trading after the company raised its full-year guidance, projecting Ibsrela revenue of $270-275 million. Q3 Ibsrela sales hit a record $78.2 million, up 92% year-over-year. CEO Mike Raab said demand growth remains strong and broad-based, positioning Ibsrela as the key driver of Ardelyx's future growth.